30.3 C
Vientiane
Wednesday, June 18, 2025
spot_img
Home Blog Page 37

FIFA Under Pressure to Kick Big Soda Out Amid Health Backlash – Vital Strategies

Global health leaders call foul on Coca-Cola’s role in the world’s game 

NEW YORK, June 3, 2025 /PRNewswire/ — A powerful coalition of global health experts and advocates is calling on FIFA to end its decades-long partnership with Coca-Cola, accusing the company of “sportswashing” the health harms linked to its sugary drinks. The Kick Big Soda Out campaign highlights how Coca-Cola’s sponsorship directly undermines FIFA’s stated commitments to health and fair play. Ahead of the 2025 FIFA Club World Cup, campaigners are urging immediate action to protect fans—especially children—from misleading brand associations.

Kick Big Soda Out gained global momentum during the 2024 Paris Olympics, with more than 255,000 petition signatories and 93 organizations calling on the International Olympic Committee to end its Coca-Cola partnership. However, a Vital Strategies report found 78% of media coverage framed Coca-Cola’s sponsorship in a favorable light, emphasizing its brand promotion, shared values or economic benefits, while only 2% of articles criticized the partnership as a primary theme—citing concerns like exploitation, health risks or unethical practices.

“FIFA claims to champion health, but its deep ties with Coca-Cola say otherwise,” said Trish Cotter, Vital Strategies. “By giving Coca-Cola a platform across stadiums, broadcasts and social media, FIFA is promoting a product linked to rising rates of obesity, Type 2 diabetes and heart disease. This is blatant ‘sportswashing,’ and it erodes both public health and FIFA’s credibility.”

Now, football fans and advocates are demanding FIFA end its partnership with Coca-Cola in the second wave of Kick Big Soda Out across YouTube, Instagram and Facebook.

“FIFA can choose to protect the integrity of football, rather than continue to give corporations an unparalleled opportunity to sanitize their image,” said Dr. Simón Barquera, President, World Obesity Federation. “By rejecting Big Soda, FIFA can finally practice what it preaches.”

Kick Big Soda Out spotlights mounting global evidence associating excess sugar consumption with noncommunicable diseases. In low-income countries—where these conditions are rising at alarming rates—Big Soda aggressively markets sugary drinks to millions of consumers.     

“This is a decisive moment for FIFA. Big Soda advertising encourages unhealthy choices among children. Restricting marketing is essential to support children’s health and wellbeing,” said Carolina Piñeros, Red PaPaz.

Supporters can join the movement demanding FIFA end its Coca-Cola partnership at www.kickbigsodaout.org and use #KickBigSodaOutofSport to join the conversation.

Media Contact:
Rachel Burns, rburns@vitalstrategies.org

CCTV+: 2025 Taklimakan Rally Concludes After thrilling 13-Day Desert Challenge

BEIJING, June 3, 2025 /PRNewswire/ — The X Power 2025 Taklimakan Rally wrapped up with roaring success on June 1 in northwest China’s Xinjiang.

Kicking off on May 20, the grueling 13-day event spanned Aksu, Hetian, and Kashi prefectures. This year’s course covered a total of 5,183 kilometers, including 2,200 kilometers of timed special stages across deserts, Gobi plains, and river crossings. A total of 23 motorcycles and 105 vehicles participated, with 233 racers from 12 countries battling extreme heat and complex terrain.

Czech rider Martin Michek and China’s Liu Yangui claimed overall victories in the motorcycle and car categories, respectively.

Michek clinched the motorcycle title with a total time of 28 hours, 31 minutes, and 4 seconds, leading a commanding performance by his team.

“This race was extremely tough, but I really enjoyed competing in China,” said Michek, who participated in the rally for the first time.

Liu secured the car division crown with a time of 27 hours, 8 minutes, and 15 seconds.

“Winning the overall title was our only goal, and it’s the greatest recognition we could receive,” Liu said, expressing gratitude to his team and all support staff.

Known as “China’s Dakar,” the Taklimakan Rally is widely regarded as the country’s most challenging cross-country rally. Since its inception in 2005, the event has continued to evolve. This year marked the debut of a New Energy Vehicle (NEV) category, with ten vehicles entering the T2.E class.

In this inaugural NEV category, Yao Weiqiang of the Great Wall Tank Hi4 Team took the title, finishing in 37 hours, 30 minutes, and 42 seconds.

The closing ceremony featured a spectacular drone performance and fireworks show, bringing celebration and relief after 13 intense days. Racers, mechanics, and support crews finally had a moment to breathe, reflect, and enjoy the joy of victory and achievement.

New Global Trade Benchmark: Envision Energy and Marubeni Sign Green Ammonia Offtake Agreement

CHIFENG, China, June 3, 2025 /PRNewswire/ — Envision Energy, a global leader in green technology, announced a historic green ammonia offtake agreement with Marubeni Corporation, one of Japan’s five major trading companies. This pioneering agreement on a global scale validates the commercial viability of green ammonia as a scalable energy solution, sets a global benchmark for its trade, and highlights the vast potential of green hydrogen-ammonia energy across the Asia-Pacific and beyond.

The partnership brings together Envision Energy’s leadership in integrated green hydrogen-ammonia solutions with Marubeni’s expansive global network and energy trade expertise, facilitating large-scale production, supply, and commercialization of green ammonia. It aims to fast-track the global transition to low-carbon energy solutions, particularly in industries such as chemicals and fertilizers, driving sustainable growth across diverse sectors worldwide. This collaboration will also accelerate Japan’s shift to a green economy, drive greater investment and innovation, and support the government’s sustainability goals.

“The global energy landscape is undergoing profound changes, with hydrogen-ammonia playing an increasingly pivotal role.” said Mr. Frank Yu, Senior Vice President of Envision Energy, “Together with Marubeni, we are accelerating the commercialization of ammonia, turning it into a key energy solution that powers the world’s transition to carbon-neutral fuels. This partnership lays the groundwork for ammonia-powered transportation and electricity generation, ultimately fostering a cleaner and more sustainable energy ecosystem.”

Envision Energy is the world’s leading green hydrogen producer and the only company that possesses core technologies in renewable energy, hydrogen production, and net-zero industrial park, targeting for decarbonization at scale by green hydrogen-ammonia solutions. By pioneering full-stack green hydrogen technologies, including alkaline and PEM electrolysis technologies, along with its engineering competences and system integration capabilities, the company aims to address key challenges in the green hydrogen arena, particularly those related to efficiency and the intermittency of renewable energy sources.

The company is at the forefront of developing the world’s largest commercial green hydrogen-ammonia plant, leveraging its innovative net-zero industrial park model and full-stack green hydrogen technologies. Fully powered by green electricity from directly coupled wind and solar energy, the plant efficiently integrates wind, solar and storage with hydrogen-ammonia production to optimize costs and enhance sustainability. The initial production phase, launched in early 2024, targets 300,000 tons of green ammonia annually and plans to scale up to a total annual capacity of 1.5 million tons upon completion. Envision’s outstanding contribution to decarbonization earned it the Energy Transition Changemaker Award at COP28 and recognition as an “Energy Innovator” on Fortune’s Change the World list in 2024.

Alphamab Oncology Presented Multiple Clinical Data of Anti-HER2 Biparatopic ADC JSKN003 at the 2025 ASCO Annual Meeting

SUZHOU, China, June 3, 2025 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that multiple clinical data updates for anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 were presented as posters at the 2025 Annual Meeting of American Society of Clinical Oncology (2025 ASCO Annual Meeting) from May 30 to June 3, 2025, in Chicago, IL, U.S.. The results covered platinum-resistant ovarian cancer, HER2-positive breast cancer, and HER2-overexpressing gastrointestinal tumors.

Title: JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials
Abstract Number for Publication: 5557
Session Type and Title: Poster Session – Gynecologic Cancer
Session Date and Time: 6/1/2025 9:00 AM-12:00 PM CDT
Presenter: Xiaohua Wu, Fudan University Shanghai Cancer Center

Methods

JSKN003-101 (NCT05494918) is a Phase I study in Australia and JSKN003-102 (NCT05744427) is a Phase I/II study in China. Both trials enrolled patients with advanced solid tumors who were to receive JSKN003 monotherapy at various dose levels. Pooled results have demonstrated that JSKN003 monotherapy has promising efficacy signals in patients with PROC, and the efficacy was observed across patients with (IHC 1+/2+/3+) or without (IHC 0) HER2 expression, with or without prior bevacizumab and prior PARP inhibitor. Preliminary data from the pooled analysis of these two studies were presented at the 2024 European Society for Medical Oncology (ESMO) Congress for the first time. The latest findings for non-primary platinum-refractory PROC patients at a longer follow-up time were reported at this ASCO Annual Meeting.

Results

As of February 28, 2025, 46 PROC patients were enrolled and received JSKN003 every three weeks across five doses levels, among which 2 patients at the dose of 4.2 mg/kg, 2 patients at the dose of 5.2 mg/kg, 40 patients at the dose of 6.3 mg/kg (RP2D), 1 patient at the dose of 7.3mg/kg, and 1 patient at the dose of 8.4mg/kg.

Efficacy: With a median follow-up time of 9.3 months, 46 patients were efficacy evaluable. 42 patients (91.3%) exhibited tumor shrinkage. The objective response rate (ORR) was 63.0%, the median progression-free survival (PFS) was 7.7 months, and the 9-month overall survival (OS) rate was 89.9%. Efficacy was observed across different HER2-expression subgroups. The ORR was 52.4% and the median PFS was 6.6 months in patients with HER2 IHC 0. The ORR reached 72.2% and the median PFS was 9.4 months in patients with HER2 expression (IHC 1+/2+/3+).

Safety: Grade 3-4 treatment-related adverse events (TRAEs) occurred in 9 patients (19.6%). Serious TRAEs were reported in 6 patients (13.0%). No TRAEs leading to death. Interstitial lung disease (ILD) was observed in 5 patients (10.9%), all were Grade 1/2.

Conclusions

With extended follow-up, JSKN003 demonstrated robust PFS improvement in PROC, along with early signals of OS benefit. A confirmatory trial (JSKN003-306, NCT06751485) is currently enrolling all comers regardless of HER2 expression to validate JSKN003 as a treatment option for this patient population.

Title: JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studies
Abstract Number for Publication: 1028
Session Type and Title: Poster Session – Breast Cancer – Metastatic
Session Date and Time: 6/2/2025 9:00 AM-12:00 PM CDT
Presenter: Yiqun Du, Fudan University Shanghai Cancer Center

Methods

The pooled analysis was performed to evaluate the efficacy and safety of JSKN003 in HER2-positive (IHC 3+ or 2+/ISH+) advanced breast cancer from the Phase I clinical trial (JSKN003-101, NCT05494918) in Australia and the Phase I/II clinical trial (JSKN003-102, NCT05744427) in China.

Results

As of February 28, 2025, the median follow-up duration was 6.1 months. A total of 88 patients with HER2-positive breast cancer were enrolled, with the majority receiving 6.3 mg/kg or 8.4 mg/kg doses. The median age was 55 years (range: 32-79), with 77.3% ECOG PS 1. All patients had stage IV disease, with 76.1% having visceral metastases. All patients had prior anti-HER2 therapy, including 85.2% with prior ADCs or TKIs, and 55.7% having at least three prior lines treatment.

Efficacy: A total of 80 T-DXd-naïve patients were enrolled, of whom 75 were evaluable for efficacy. In this population (N=75), JSKN003 demonstrated a confirmed ORR of 54.7% (95% CI: 42.7-66.2). The disease control rate (DCR) and clinical benefit rate (CBR) were 94.7% and 66.7%, respectively.

Among 30 patients treated at the RP2D of 6.3 mg/kg, the confirmed ORR was 73.3%, and CBR reached 83.3%. Subgroup analyses by line of therapy showed ORRs of 66.7% in the prior first line group of 15 patients and 63.2% in the prior second line group of 19 patients, respectively.

In addition, 8 patients who had previously received T-DXd were enrolled, among whom 7 had evaluable efficacy data. One patient achieved a partial response (PR), four had stable disease (SD), and tumor shrinkage was observed in four patients. These patients were analyzed separately for exploratory purposes.

The median duration of response (DoR) in the overall population was 18.4 months (95% CI: 9.9-NE). Median PFS was not mature at the time of data cutoff. The 3-month and 6-month PFS rates were 88.4% (95% CI: 78.8–93.8) and 75.4% (95% CI: 62.3–84.4), respectively.

Safety: 15.9% of patients experienced Grade 3 or higher TRAEs. Serious TRAEs were reported in 5.7% of patients. Dose reductions due to TRAEs occurred in 12.5% of patients, and one patient discontinued due to a TRAE. No TRAEs led to death. The most common TRAEs (≥20%) were nausea, increased alanine aminotransferase, decreased white blood cell count, vomiting, anemia, decreased appetite, thrombocytopenia, fatigue, neutropenia, and diarrhea. ILD was reported in 4 patients (4.5%), mostly Grade 1-2; one case was Grade 3.

Conclusions

JSKN003 demonstrated promising antitumor activity and manageable safety in heavily pretreated HER2-positive breast cancer, including patients previously treated with T-DXd. Its biparatopic HER2 antibody design may enhance target binding and contribute to the observed clinical benefit. A pivotal Phase III trial (JSKN003-301, NCT06846437) is ongoing to compare JSKN003 with T-DM1 in patients with HER2-positive advanced breast cancer who were previously treated with trastuzumab.

Title: A pooled analysis of JSKN003, a biparatopic anti-HER2 antibody conjugate (ADC), in patients with advanced HER2-overexpressing (IHC 3+) gastrointestinal tumors
Abstract Number for Publication: 3022
Session Type and Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Session Date and Time: 6/2/2025 1:30 PM-4:30 PM CDT
Presenter: Dan Liu, Beijing Cancer Hospital

Methods

The pooled analysis was performed to evaluate the efficacy and safety of JSKN003 in HER2-overexpressing (IHC 3+) metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJC) and colorectal cancer (CRC) patients from the Phase I clinical trial (JSKN003-101, NCT05494918) in Australia and the Phase I/II clinical trial (JSKN003-102, NCT05744427) in China.

Results

As of February 28, 2025, a total of 50 patients with HER2-overexpressing gastrointestinal tumors (27 patients in GC/GEJC and 23 patients in CRC) were enrolled and treated with JSKN003 monotherapy across 7 dose levels: 1 patient at the dose of 2.1 mg/kg, 1 patient at the dose of 4.2 mg/kg, 1 patient at the dose of 5.2 mg/kg, 43 patients at the dose of 6.3 mg/kg, 1 patient at the dose of 7.3 mg/kg, 2 patients at the dose of 8.4 mg/kg and 1 patient at the dose of 10.5 mg/kg. The median age was 60 years (range: 52-66), with 86.0% ECOG PS 1. Most patients were heavily pretreated: 38.0% had at least three lines of prior therapies, 68.0% received anti-HER2 therapy, 48.0% received Irinotecan.

Efficacy: Among 48 patients who had at least one tumor assessment after baseline, JSKN003 demonstrated the ORR of 62.5% and the DCR was 93.8%. Among 27 patients with GC/GEJC, the ORR was 63.0% and DCR reached 92.6%. Among 21 patients with CRC, the ORR was 61.9% and DCR reached 95.2%. Among twenty patients with BRAF V600E-wild type, the ORR was 65.0%.

Additionally, among 24 patients (4 patients in GC/GEJC and 20 patients in CRC) who were pretreated with irinotecan, the ORR achieved 58.3%.

The median DoR in GC/GEJC patients was 9.6 months (95% CI: 3.0-NE), while the median DoR in CRC patients was 12.1 months (95% CI: 5.8-NE). Median PFS was 9.6 months (95%CI: 4.3, 11.6) with 70.4% PFS rate at 6 months in GC/GEJC patients. Median PFS was 13.8 months (95% CI: 6.8, NE) with 88.9% PFS rate at 6 months in CRC patients.

Safety: 18.0% of patients experienced Grade 3 or higher TRAEs. Serious TRAEs were reported in 6.0% of patients. Dose reduction due to TRAEs occurred in 20.0% of patients and 16.3% at RP2D. No TEAEs led to discontinuation or death. The most common TRAEs (≥20%) were nausea, diarrhea, decreased appetite, decreased white blood cell count, anemia, fatigue, decreased neutrophil count, decreased platelet count and vomiting. ILD was reported in 3 patients (6.0%), with Grade 1 in 2 patients and Grade 2 in 1 patient.

Conclusions

JSKN003 demonstrated promising efficacy in heavily pretreated HER2-overexpressing (IHC3+) gastrointestinal tumors including patients previously treated with irinotecan, with a manageable and predictable safety profile. The HER2 biparatopic ADC design may contribute to the observed clinical benefit.

About JSKN003

JSKN003 is a bispecific ADC developed based on KN026 using Alphamab’s proprietary glycan-specific conjugation platform. JSKN003 can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exerting anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window.

Results of multiple clinical studies at various stages of JSKN003 in China and Australia have demonstrated favorable safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with platinum-resistant ovarian cancer (PROC), HER2-expressing breast cancer (BC), or high HER2-expressing solid tumors. JSKN003 was granted breakthrough therapy designation by CDE. The designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Three Phase III clinical studies of JSKN003 for the treatment of HER2-low expressing BC, PROC, and HER2-positive BC as well as multiple exploratory Phase II clinical studies are currently undergoing smoothly.

In September 2024, the Company entered a licensing agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), pursuant to which, JMT-Bio was granted the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003, for the treatment of tumor-related indications (the “Field”) in mainland China (excluding Hong Kong, Macau or Taiwan) (the “Territory”) and become the sole marketing authorization holder for JSKN003 for the Field in the Territory. Alphamab retains the sole right to supply JSKN003.

About Alphamab Oncology

Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies.

The Company has one product approved for marketing (Envafolimab, the world’s first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.

Tineco Updates S9 Line-up with S9 Artist Steam Floor Washers for an Even Better Cleaning Experience

  • Tineco launches the S9 Artist Steam—the latest addition to their best-selling S9 lineup.
  • Experience the ultimate clean with this innovative floor washer, where cutting-edge technology meets energy efficiency and sleek design for unmatched performance.
  • To complement the launch, exclusive brand-led promotions will be available on selected online platforms for purchases made on 6 June.

SINGAPORE – Media OutReach Newswire – 3 June 2025 – Tineco, a global leader in smart cleaning technology, today announced the launch of the S9 Artist Steam on 6 June, a powerful upgrade to Tineco’s top-performing S9 range, complete with a line-up of attractive promotional offers. This new innovative addition comes with upgrades to enhance cleaning experience, including HyperSteam Technology, Flash Charging and more.

Tineco S9 Artist Steam
Tineco S9 Artist Steam

Supercharged With Tineco’s Latest Technology To Give You The Ultimate Cleaning Experience

Engineered for performance, precision, and modern lifestyles, the S9 Artist Steam brings together HyperSteam technology and AI-driven smart maintenance, earning the title of “The Ultimate Cleaning, Redefined with Unique Style” for homes.

The S9 Artist Steam introduces several key upgrades from its predecessor, further enhancing its performance and convenience. One of the most notable improvements is the 140°C HyperSteam technology, along with its Dual-Stage Heating that targets oil and grime with unmatched efficiency, outperforming traditional single-stage systems that leave residue behind. This ensures deeper sanitation by dissolving stubborn dirt and bacteria more effectively.

Runtime has also been significantly extended, with the new model delivering up to 75 minutes of operation on a single charge—a notable increase from the S9 Artist’s 50-minute capacity. This offers users more time and coverage without interruption. In addition, the introduction of Flash Charging technology allows the device to recharge more rapidly while the 2A fast charging doubles the speed for quick readiness – minimising downtime between uses.

Meanwhile, the 22kPa Powerful Suction, deep-cleans floor crevices, instantly removing dust and debris. Finally, the Triple-sided Edge Cleaning feature replaces the earlier double-sided system to ensure even more thorough cleaning along walls and baseboards.

Tineco S9 Artist Steam
Tineco S9 Artist Steam

To mark the launch of the S9 Artist Steam, Tineco will roll out exclusive promotions across all official retail channels from 6 June. Customers purchasing through Tineco’s official website, Lazada and Shopee flagship stores on 6 June, will enjoy a host of value-added benefits.

Availability & Launch Promotions

Device Availability Key Features Launch Promotions

T&Cs apply, while stocks last

Floor One S9 Artist Steam Available now on Shopee, Lazada, TikTok Shop and Mass Retailers – 284°F (140°C) HyperSteam Technology

– Triple-sided Edge Cleaning

– 75-Minute Runtime

– Triple-sided Edge Cleaning

Free Tineco iCarpet Spot Cleaner (worth S$379) + 6 bottles of cleaning solution

Hashtag: #Tineco

The issuer is solely responsible for the content of this announcement.

About Tineco

Founded in 1998, Tineco is a high-tech company and a wholly-owned subsidiary of ECOVACS Group (SHA: 603486). Dedicated to innovation, Tineco has consistently delivered smart home cleaning solutions that redefine convenience and efficiency. With the launch of the Floor One S9 Artist and Floor One Switch S7 Stretch, Tineco continues to lead the way in creating products that make everyday life easier and more enjoyable.

Vectra AI Named a Leader in the First-Ever Gartner® Magic Quadrant for Network Detection and Response

Recognized for the Strength of its AI-Driven NDR Platform, Vectra AI is Positioned Furthest for Completeness of Vision and Highest for Ability to Execute in the Inaugural Report

SINGAPORE, June 3, 2025 /PRNewswire/ — Vectra AI, Inc., the cybersecurity AI company that protects modern networks from modern attacks, today announced it was named a Leader in the 2025 Gartner® Magic Quadrant for Network Detection and Response (NDR). Vectra AI is positioned highest for Ability to Execute and furthest for Completeness of Vision, and is the only vendor in the report to be named a leader in both the Gartner Magic Quadrant for NDR and a Customer Choice Winner for NDR in the 2024 Gartner Peer Insights Voice of the Customer.

The Vectra AI Platform is purpose-built to defend modern hybrid environments from identity and network-based attacks. As threats accelerate across cloud, data center, remote, and OT domains, Vectra AI provides comprehensive coverage to reduce attack exposure. Its AI agents continuously triage, correlate, and prioritize real threats in real time – eliminating alert fatigue and accelerating response. With Vectra AI, defenders gain control to detect, hunt, investigate, and respond to attacks across the full threat landscape, enabling security teams to focus on maturing their security posture.

“Gartner’s decision to publish a Magic Quadrant for NDR reflects just how essential this market has become in modern cyber defense,” said Hitesh Sheth, founder and CEO of Vectra AI. “Being recognized as a Leader in this inaugural report reinforces Vectra AI’s position at the forefront of this critical space. As organizations grapple with growing complexity, identity-based attacks, and AI-driven threats, the Vectra AI Platform delivers what modern defenders need – coverage that reduces exposure, clarity that cuts through the noise, and control to act with speed and confidence.”

Vectra AI has been recognized by customers for outstanding product performance and support, earning the distinction of Customers’ Choice in the 2024 Gartner® Peer Insights™ Voice of the Customer for Network Detection and Response. As of January 2024, Vectra AI holds a 4.8 out of 5 rating based on 96 reviews, with 96% of customers saying they would recommend the platform. This recognition reflects Vectra AI’s deep commitment to customer success and ongoing innovation in protecting modern networks from modern attacks.

Download the full Magic Quadrant for Network Detection and Response here.

Arctech celebrates five years of growth in Argentina and reinforces its commitment to the Southern Cone and LATAM

KUNSHAN, China, June 3, 2025 /PRNewswire/ — Arctech, a global leader in solar structure and tracker solutions with smart renewable energy technologies, is celebrating its fifth anniversary in Argentina, highlighting a trajectory defined by innovation, local commitment, and a regional development vision for the Southern Cone.

At a special event held with clients, strategic partners, and members of the regional team, Arctech commemorated this milestone as an opportunity to reflect on the achievements and challenges overcome during five years of operations in the country. It was also a space to share the company’s growth objectives as it continues consolidating its presence across Latin America.

“This anniversary is a recognition of the joint work carried out with our clients, strategic partners, and the Arctech LATAM South team. Every step we’ve taken has been possible thanks to their trust and collaboration. We look to the future with excitement, knowing that the future of solar energy in LATAM is built on cooperation, technology, and commitment,” said Alejandro Silva Zamora, Director LATAM South & Brazil.

Since arriving in Argentina, Arctech has participated in some of the country’s most prominent solar projects. With a presence across several provinces, the company has provided cutting-edge technology in developments such as Guañizuil II (117 MW), La Rioja Solar (35 MW), Anchipurac (23 MW), Ullum (25 MW), La Cumbre (15.6 MW), and Tucumán Solar (6 MW), among others. These projects reflect the technical and operational efforts of a committed regional team and a technology offering that stands out for its adaptability, efficiency, and reliability factors that position Arctech above other solutions in the market.

Five years after its arrival in the country, Arctech reaffirms its commitment to delivering a reliable experience supported by local talent and technical service. The company also seeks to continue expanding long-term relationships that enable sustainable projects with regional impact.

About Arctech
Arctech is a global provider of intelligent solar solutions with over 91 GW delivered in more than 40 countries. Its portfolio includes solar trackers, fixed structures, PV cleaning robots, and energy storage systems. In Latin America, the company has a strong presence and a team of over 60 professionals, positioning itself as a strategic partner in the region’s energy transformation.

Kalkine Australia’s The Funds Report: Ranking Australian Managed Funds and ETFs

SYDNEY, June 3, 2025 /PRNewswire/ — Kalkine Australia recently launched its “The Funds Report, a research-driven publication that provides structured, objective rankings of Managed funds and exchange-traded funds (ETFs) listed on the Australian Securities Exchange (ASX). Developed by Kalkine’s in-house research team, the report is designed to help subscribers better understand and compare fund performance through a consistent, data-driven framework.

Kalkine’s The Funds Report delivers objective ranking of Managed funds and ETFs based on a defined set of performance, risk, and cost metrics. This allows users to make informed decisions by reviewing how various funds stack up against each other across key indicators.

Data-Driven Fund Ranking Based on Key Metrics

The report evaluates and ranks funds based on several quantifiable performance measures, including but not limited to the metrics below:

  • Alpha generation – Fund performance relative to benchmark indexes.
  • Sharpe ratio – Risk-adjusted returns assessing reward per unit of risk.
  • Three-year annualised returns – Historical performance over a meaningful timeframe.
  • Total expense ratio – Cost efficiency over time.

ASX listed Managed Funds or Exchange Traded Funds are grouped by thematic categories, enabling subscribers to easily identify and compare funds aligned with specific investment strategies or market sectors. This objective approach enhances transparency in fund evaluation.

Comprehensive Insights to Navigate the Australian Fund Market

Kalkine Australia’s TheFunds Report provides extensive analysis of Australian fund performance, helping users navigate the growing variety of options available on the ASX. Features include:

  • Regular Updates on New and Sector-Specific Funds: Stay informed about recent listings and sector specific funds.
  • Detailed Performance Breakdown: Analysis across equities, fixed income, and alternative asset classes.
  • Risk and Return Profiles: Clear insights into risk-adjusted returns to support balanced investment information.
  • Fund Comparison Tools: Side-by-side comparison covering historical returns, fees, asset allocation, and investment styles.
  • Thematic Categorization: Organized by market themes and strategies to analyze diversified and trending investment areas.

A Comparative Resource

Kalkine Australia’s TheFunds Report is designed to assist both individual investors and financial professionals seeking a clear and structured way to compare ASX-listed funds. The report ranks the funds based on scores derived and offers valuable data and insights to complement comprehensive due diligence and research.

About Kalkine

Kalkine operates globally, providing an independent equity research services across Australia, the United States, the United Kingdom, Canada, India, and New Zealand. Kalkine Pty Ltd delivers technology-driven, timely financial research to its subscribers. Its unique engagement model ensures high-impact content and deeper insights, maintaining its position as a player in accessible financial research. 

For more information or to subscribe, visit: https://www.kalkine.com.au
Vivek Samnotra
Kalkine Pty Ltd
+61- (02) 90559490
info@kalkine.com.au